Downstream biomarker effects of gantenerumab or solanezumab in dominantly inherited Alzheimer disease: The DIAN-TU-001 randomized clinical trial

Authors

• Olivia Wagemann, Washington University School of Medicine in St. Louis
• Haiyan Liu, Washington University School of Medicine in St. Louis
• Guoqiao Wang, Washington University School of Medicine in St. Louis
• Xinyu Shi, Washington University School of Medicine in St. Louis
• David B Clifford, Washington University School of Medicine in St. Louis
• Charlene Supnet-Bell, Washington University School of Medicine in St. Louis
• Anna M Santacruz, Washington University School of Medicine in St. Louis
• Andrew J Aschenbrenner, Washington University School of Medicine in St. Louis
• Jason J Hassenstab, Washington University School of Medicine in St. Louis
• Tammie L S Benzinger, Washington University School of Medicine in St. Louis
• Brian A Gordon, Washington University School of Medicine in St. Louis
• Carlos Cruchaga, Washington University School of Medicine in St. Louis
• Laura Ibanez, Washington University School of Medicine in St. Louis
• Richard J Perrin, Washington University School of Medicine in St. Louis
• Chengjie Xiong, Washington University School of Medicine in St. Louis
• Yan Li, Washington University School of Medicine in St. Louis
• John C Morris, Washington University School of Medicine in St. Louis
• Jorge Llibre-Guerra, Washington University School of Medicine in St. Louis
• Randall J Bateman, Washington University School of Medicine in St. Louis
• Eric McDade, Washington University School of Medicine in St. Louis
• et al.

Journal

JAMA Neurology

Publication Date

6-1-2024

Volume

81

Issue

6

First Page

582

Last Page

593

Document Type

Open Access Publication

DOI

10.1001/jamaneurol.2024.0991

Rights and Permissions

Wagemann O, Liu H, Wang G, et al. Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial. JAMA Neurol. 2024;81(6):582–593. doi:10.1001/jamaneurol.2024.0991. This is an open access article distributed under the terms of the CC-BY License. © 2024 Wagemann O et al. JAMA Neurology.

Recommended Citation

Wagemann, Olivia; Liu, Haiyan; Wang, Guoqiao; Shi, Xinyu; Clifford, David B; Supnet-Bell, Charlene; Santacruz, Anna M; Aschenbrenner, Andrew J; Hassenstab, Jason J; Benzinger, Tammie L S; Gordon, Brian A; Cruchaga, Carlos; Ibanez, Laura; Perrin, Richard J; Xiong, Chengjie; Li, Yan; Morris, John C; Llibre-Guerra, Jorge; Bateman, Randall J; McDade, Eric; and et al., "Downstream biomarker effects of gantenerumab or solanezumab in dominantly inherited Alzheimer disease: The DIAN-TU-001 randomized clinical trial." JAMA Neurology. 81, 6. 582 - 593. (2024).
https://digitalcommons.wustl.edu/oa_4/7679

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.